JP6499175B2 - 三環式ベンゾキサボロール化合物及びその使用 - Google Patents

三環式ベンゾキサボロール化合物及びその使用 Download PDF

Info

Publication number
JP6499175B2
JP6499175B2 JP2016533471A JP2016533471A JP6499175B2 JP 6499175 B2 JP6499175 B2 JP 6499175B2 JP 2016533471 A JP2016533471 A JP 2016533471A JP 2016533471 A JP2016533471 A JP 2016533471A JP 6499175 B2 JP6499175 B2 JP 6499175B2
Authority
JP
Japan
Prior art keywords
mycobacterium
compound
tuberculosis
pharmaceutically acceptable
borabenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016533471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527321A5 (enExample
JP2016527321A (ja
Inventor
アリー，エム．アール．ケー．ディクソン
エス． エルナンデス，ヴィンセント
エス． エルナンデス，ヴィンセント
ジェイ． プラットナー，ジェイコブ
ジェイ． プラットナー，ジェイコブ
リー，シャンフェン
バロス−アギルレ，デイヴィット
ジョルダーノ，イラーリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2016527321A publication Critical patent/JP2016527321A/ja
Publication of JP2016527321A5 publication Critical patent/JP2016527321A5/ja
Application granted granted Critical
Publication of JP6499175B2 publication Critical patent/JP6499175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016533471A 2013-08-09 2014-08-08 三環式ベンゾキサボロール化合物及びその使用 Active JP6499175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361864496P 2013-08-09 2013-08-09
US61/864,496 2013-08-09
US201361918976P 2013-12-20 2013-12-20
US61/918,976 2013-12-20
PCT/US2014/050370 WO2015021396A2 (en) 2013-08-09 2014-08-08 Tricyclic benzoxaborole compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019046582A Division JP6764970B2 (ja) 2013-08-09 2019-03-14 三環式ベンゾキサボロール化合物及びその使用

Publications (3)

Publication Number Publication Date
JP2016527321A JP2016527321A (ja) 2016-09-08
JP2016527321A5 JP2016527321A5 (enExample) 2018-01-18
JP6499175B2 true JP6499175B2 (ja) 2019-04-10

Family

ID=52462052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016533471A Active JP6499175B2 (ja) 2013-08-09 2014-08-08 三環式ベンゾキサボロール化合物及びその使用
JP2019046582A Active JP6764970B2 (ja) 2013-08-09 2019-03-14 三環式ベンゾキサボロール化合物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019046582A Active JP6764970B2 (ja) 2013-08-09 2019-03-14 三環式ベンゾキサボロール化合物及びその使用

Country Status (35)

Country Link
US (5) US20160251380A1 (enExample)
EP (2) EP3030519B1 (enExample)
JP (2) JP6499175B2 (enExample)
KR (1) KR102093783B1 (enExample)
CN (2) CN105492388B (enExample)
AP (1) AP2016009046A0 (enExample)
AU (2) AU2014305792C1 (enExample)
BR (1) BR112016002651B1 (enExample)
CA (1) CA2919888C (enExample)
CL (1) CL2016000313A1 (enExample)
CR (1) CR20160064A (enExample)
CY (1) CY1125030T1 (enExample)
DK (1) DK3030519T3 (enExample)
DO (1) DOP2016000045A (enExample)
EA (1) EA032844B1 (enExample)
ES (1) ES2905413T3 (enExample)
HR (1) HRP20220384T1 (enExample)
HU (1) HUE057365T2 (enExample)
IL (1) IL243874B (enExample)
LT (1) LT3030519T (enExample)
MX (1) MX375556B (enExample)
MY (1) MY175823A (enExample)
NZ (1) NZ716350A (enExample)
PE (1) PE20160752A1 (enExample)
PH (1) PH12016500234B1 (enExample)
PL (1) PL3030519T3 (enExample)
PT (1) PT3030519T (enExample)
RS (1) RS62887B1 (enExample)
SA (1) SA516370551B1 (enExample)
SG (2) SG10201914073PA (enExample)
SI (1) SI3030519T1 (enExample)
SM (1) SMT202200113T1 (enExample)
UA (1) UA116908C2 (enExample)
WO (1) WO2015021396A2 (enExample)
ZA (1) ZA201600792B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019123727A (ja) * 2013-08-09 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 三環式ベンゾキサボロール化合物及びその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094961A1 (es) * 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
CN106459097A (zh) 2014-07-01 2017-02-22 第三共株式会社 作为抗菌剂的三环苯并氧杂硼杂环戊烯类
MA41495A (fr) * 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
PE20190119A1 (es) 2016-05-12 2019-01-17 Anacor Pharmaceuticals Inc Esteres de oxaborol y sus usos
CN109387594B (zh) * 2017-08-08 2021-01-19 武汉武药科技有限公司 一种分离和分析贝达喹啉光学异构体的方法
ES2949908T3 (es) * 2018-01-09 2023-10-03 Halcyon Labs Private Ltd Proceso para la preparación de Crisaborol y sus intermedios
EP4164645A4 (en) * 2020-06-15 2024-07-10 The Global Alliance for TB Drug Development, Inc. COMBINED ANTIBACTERIAL COMPOSITION AND ANTIBACTERIAL THERAPY METHOD
CN111606850B (zh) * 2020-07-07 2023-07-25 安徽贝克生物制药有限公司 贝达喹啉及其中间体的制备方法
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CA3239097A1 (en) 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Prodrugs of boron compounds and their use in treating bacterial infections
JP2025520237A (ja) * 2022-06-23 2025-07-03 ミクウルク ファーマシューティカルズ， インコーポレイテッド ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
WO2024208907A1 (en) 2023-04-05 2024-10-10 Glaxosmithkline Intellectual Property (No. 2) Limited Synthesis of 3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3h)-ol
CN117379430B (zh) * 2023-10-11 2026-07-21 深圳市第三人民医院(深圳市肝病研究所) 一种地拉韦啶的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024753A1 (en) 1996-12-02 1998-06-11 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
CN101505603A (zh) * 2005-12-30 2009-08-12 安纳考尔医药公司 含硼的小分子
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
SG172040A1 (en) 2008-12-17 2011-07-28 Anacor Pharmaceuticals Inc Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
AU2011237681B2 (en) * 2010-04-07 2015-01-22 Glaxosmithkline Llc Process for preparing benzoxaboroles
DK2613788T3 (en) * 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
US8530452B2 (en) * 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
MA41495A (fr) * 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019123727A (ja) * 2013-08-09 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 三環式ベンゾキサボロール化合物及びその使用

Also Published As

Publication number Publication date
RS62887B1 (sr) 2022-03-31
SA516370551B1 (ar) 2017-10-31
US20160251380A1 (en) 2016-09-01
CN110003253A (zh) 2019-07-12
CN105492388B (zh) 2018-12-21
AU2014305792A1 (en) 2016-03-10
WO2015021396A2 (en) 2015-02-12
CN110003253B (zh) 2022-03-18
PE20160752A1 (es) 2016-08-17
SG11201600787PA (en) 2016-03-30
AP2016009046A0 (en) 2016-02-29
US20210053999A1 (en) 2021-02-25
HK1219939A1 (zh) 2017-04-21
ES2905413T3 (es) 2022-04-08
JP6764970B2 (ja) 2020-10-07
US20200095266A1 (en) 2020-03-26
PT3030519T (pt) 2022-01-27
DK3030519T3 (da) 2022-01-31
EP3030519A2 (en) 2016-06-15
CN105492388A (zh) 2016-04-13
DOP2016000045A (es) 2016-04-29
SI3030519T1 (sl) 2022-04-29
CL2016000313A1 (es) 2016-09-23
MX375556B (es) 2025-03-06
HUE057365T2 (hu) 2022-05-28
JP2019123727A (ja) 2019-07-25
CA2919888C (en) 2022-10-18
US10858376B2 (en) 2020-12-08
AU2017210567B2 (en) 2019-08-01
KR102093783B1 (ko) 2020-03-26
AU2014305792B2 (en) 2017-05-04
HRP20220384T1 (hr) 2022-07-22
AU2014305792C1 (en) 2018-07-05
US20180044355A1 (en) 2018-02-15
SG10201914073PA (en) 2020-03-30
WO2015021396A9 (en) 2016-02-11
PH12016500234B1 (en) 2019-01-30
KR20160038901A (ko) 2016-04-07
CR20160064A (es) 2016-06-01
PL3030519T3 (pl) 2022-05-23
WO2015021396A3 (en) 2015-10-29
US20190241586A1 (en) 2019-08-08
IL243874B (en) 2018-11-29
JP2016527321A (ja) 2016-09-08
IL243874A0 (en) 2016-04-21
UA116908C2 (uk) 2018-05-25
US10308668B2 (en) 2019-06-04
BR112016002651B1 (pt) 2022-11-29
NZ716350A (en) 2022-12-23
MX2016001732A (es) 2016-05-18
EP3030519A4 (en) 2017-03-08
US10526352B2 (en) 2020-01-07
EP3030519B1 (en) 2022-01-05
PH12016500234A1 (en) 2016-05-16
ZA201600792B (en) 2022-05-25
EA032844B1 (ru) 2019-07-31
MY175823A (en) 2020-07-10
EP4029870A1 (en) 2022-07-20
CA2919888A1 (en) 2015-02-12
LT3030519T (lt) 2022-04-11
SMT202200113T1 (it) 2022-05-12
EA201690135A1 (ru) 2016-07-29
BR112016002651A2 (pt) 2017-08-01
CY1125030T1 (el) 2023-03-24
AU2017210567A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
JP6764970B2 (ja) 三環式ベンゾキサボロール化合物及びその使用
TWI730953B (zh) 苯并氧雜硼化合物及其用途
HK1219939B (en) Tricyclic benzoxaborole compounds and uses thereof
OA17674A (en) Tricyclic benzoxaborole compounds and uses thereof.
EA038093B1 (ru) Способ лечения заболевания, вызванного инфекцией комплекса mycobacterium tuberculosis, с использованием (s)-(3-хлор-7,8-дигидро-2h-1,6,9-триокса-9a-борабензо[cd]азулен-2-ил)метанамина или его фармацевтически приемлемой соли

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190314

R150 Certificate of patent or registration of utility model

Ref document number: 6499175

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250